^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

dinaciclib (MK-7965)

i
Company:
Ligand, Merck (MSD)
Drug class:
CDK inhibitor
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/04/2025
Initiation :
11/11/2011
Primary completion :
03/28/2023
Completion :
08/02/2025
BRCA1 • BRCA2 • BRCA • RAD51
|
BRCA mutation
|
veliparib (ABT-888) • dinaciclib (MK-7965)
Phase 1b
Jo Chien
Completed
Last update posted :
09/21/2022
Initiation :
12/28/2016
Primary completion :
06/30/2020
Completion :
02/28/2022
PGR
|
PGR expression
|
Keytruda (pembrolizumab) • dinaciclib (MK-7965)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
03/30/2018
Initiation :
08/21/2012
Primary completion :
09/10/2013
Completion :
09/10/2013
HER-2 • ER • PGR • MCL1
|
HER-2 amplification • HER-2 negative
|
epirubicin • dinaciclib (MK-7965)
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/05/2015
Initiation :
07/01/2008
Primary completion :
06/01/2011
Completion :
06/01/2011
HER-2
|
HER-2 positive
|
erlotinib • capecitabine • dinaciclib (MK-7965)